Brian Feroldi

Brian Feroldi


Brian Feroldi has been covering the healthcare and technology industries for the Motley Fool since 2015. Brian's investing goal is to find the highest quality companies that he can find, buy them, and then to sit back and let compounding work its magic. See all of his articles here and make sure you follow him on Twitter.

Recent articles

Is DocuSign a Buy?

The e-signature leader just went public. Is the company's growth story compelling enough to convince investors to hop on board?

3 Hot Stocks to Buy in November

These three stocks are up big in 2018. Here's why investors should expect the good times to continue.

Is DocuSign, Inc. a Buy?

Shares of the e-signature solutions have fallen back to earth. Is now a good time to sign on as a shareholder?

Why Abiomed Plunged Today

Shares tumbled after the company reports good news. Here's what investors need to know.

Why ViewRay Inc. Is Sinking Today

Shares plunge after the company reports third-quarter results that missed the mark and lowers guidance. Is something wrong with the business?

Why Skyworks Is Tumbling Today

Shares take a step back after management warns that its near-term growth rate is about to turn negative.

New Relic's Business Is Booming

Revenue growth soars as existing customers continue to spend more on the company's application performance management platform.

Here's Why Infinera Stock Is Cratering Today

Shares crashed after the company reported weak third-quarter results and issued guidance well below expectations. Here are the must-know details for investors.